Precigen, Inc. (PGEN)
NASDAQ:PGEN
Want to see PGEN full AI Analyst Report?
PGEN Stock Chart & Stats
$3.98
-$0.11(-8.33%)
At close: 4:00 PM EST
$3.98
-$0.11(-8.33%)
Day’s Range― - ―
52-Week Range$1.38 - $5.47
Previous CloseN/A
Volume729.99K
Average Volume (3M)4.26M
Market Cap
$1.61B
Enterprise Value$1.39B
Total Cash (Recent Filing)$56.25M
Total Debt (Recent Filing)$98.25M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 10, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding356,511,000
10 Day Avg. Volume5,533,808
30 Day Avg. Volume4,263,914
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)60.91
Price to Sales (P/S)131.52
P/FCF Ratio-14.18
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue44.14
Enterprise Value/Gross Profit58.36
Enterprise Value/Ebitda-7.14
Forecast
1Y Price Target
$12.50Price Target Upside214.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$124.43M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue RampA rapid first-quarter commercial revenue ramp demonstrates tangible product-market fit and validates the company’s ability to convert clinical assets into sales. Sustained adoption over months supports recurring revenue potential, reduces reliance on milestone payments, and materially strengthens prospects for future cash generation.
Broad Payer Coverage & Reimbursement CodingExtensive payer coverage combined with a permanent J-code removes important reimbursement barriers, enabling durable access and faster claims processing. This structural access advantage supports steady demand, easier scaling into community settings, and more predictable revenue collection over the medium term.
Clinical Durability & Expert EndorsementThree-year durability data and a landmark expert position paper supporting first-line use are durable competitive advantages. They help drive clinician adoption, justify reimbursement, and build formulary/standard-of-care positioning that can sustain demand and reduce commercial churn over multiple years.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow indicate the business still consumes substantial capital to fund commercialization and pipeline work. Continued high burn narrows runway, raises financing or dilution risk if revenue collections or cost reductions underperform, and limits optionality for new investments.
Elevated LeverageA materially higher debt burden relative to equity increases refinancing and covenant risk, especially amid operating losses. High leverage constrains strategic flexibility, raises interest and fixed-cost pressure, and could force dilutive financing or curtailed R&D/commercial investments if cash generation lags.
Low Gross Margin & Ongoing LossesA single-digit-to-low double-digit gross margin limits the company’s ability to scale profits without sustained high volume or improved product economics. Coupled with sizable operating losses and rising SG&A for launch activities, margin pressure makes durable profitability contingent on continued high uptake and cost discipline.
Precigen News
PGEN FAQ
What was Precigen, Inc.’s price range in the past 12 months?
Precigen, Inc. lowest stock price was $1.38 and its highest was $5.46 in the past 12 months.
What is Precigen, Inc.’s market cap?
Precigen, Inc.’s market cap is $1.61B.
When is Precigen, Inc.’s upcoming earnings report date?
Precigen, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 59 days.
How were Precigen, Inc.’s earnings last quarter?
Precigen, Inc. released its earnings results on May 13, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.034 by $0.014.
Is Precigen, Inc. overvalued?
According to Wall Street analysts Precigen, Inc.’s price is currently Undervalued.
Does Precigen, Inc. pay dividends?
Precigen, Inc. does not currently pay dividends.
What is Precigen, Inc.’s EPS estimate?
Precigen, Inc.’s EPS estimate is -0.01.
How many shares outstanding does Precigen, Inc. have?
Precigen, Inc. has 356,511,000 shares outstanding.
What happened to Precigen, Inc.’s price movement after its last earnings report?
Precigen, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.034. Following the earnings report the stock price went up 10.843%.
Which hedge fund is a major shareholder of Precigen, Inc.?
Currently, no hedge funds are holding shares in PGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Precigen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (214.07% Upside)
$12.50 (214.07% Upside)
Blogger Sentiment
Bullish
PGEN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
202.00%
12-Months-Change
Fundamentals
Return on Equity
-1768.51%
Trailing 12-Months
Asset Growth
7.64%
Trailing 12-Months
Company Description
Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
PGEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for PAPZIMEOS with a rapid revenue ramp, broad payer coverage, expert endorsement, and promising clinical durability data — all signaling an impactful product launch. The company also faces near-term operational challenges including elevated quarter cash burn, increased SG&A tied to commercialization, timing of cash collections, and limited disclosure of granular conversion metrics. Management expects cash consumption to moderate in Q2 and projects runway to cash-flow breakeven by end-2026, which, together with the strong launch indicators, supports a constructive outlook.View all PGEN earnings summariesPGEN Stock 12 Month Forecast
Average Price Target
$12.50
▲(214.07% Upside)
Technical Analysis
MiMedx Group
―
Wave Life Sciences
―
Oric Pharmaceuticals
―
Immunome
―
Praxis Precision Medicines
―
Ownership Overview
35.66% Insiders
12.26% Mutual Funds
15.09% Other Institutional Investors
28.77% Public Companies and
Individual Investors